Related Experiment Video
Updated: Aug 7, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice
Thomas van Groen1, Amanda J Kiliaan, Inga Kadish
1Department of Neuroscience and Neurology, University of Kuopio, Finland. vangroen@uab.edu
Abstract:
The deposition of amyloid beta (Abeta) peptides and neurofibrillary tangles are the two characteristic pathological features of Alzheimer's disease (AD). To investigate the relation between amyloid precursor protein (APP) production, amyloid beta deposition and the type of Abeta in deposits, i.e., human and/or mouse, we performed a histopathological analysis, using mouse and human specific antibodies, of the neocortex and hippocampus in 6, 12 and 19 months old APP/PS1 double and APP and PS1 single transgenic mice. There was a significant correlation between the human amyloid beta deposits and the intrinsic rodent amyloid beta deposits, that is, all plaques contained both human and mouse Abeta, and the diffuse amyloid beta deposits also colocalized human and mouse Abeta. Furthermore, some blood vessels (mainly leptomeningeal vessels) show labeling with human Abeta, and most of these vessels also label with mouse Abeta. Our findings demonstrate that the human amyloid deposits in APP/PS1 transgenic mice are closely associated with mouse Abeta, however, they do not precisely overlap. For instance, the core of plaques consists of primarily human Abeta, whereas the rim of the plaque contains both human and mouse amyloid beta, similarly, human and mouse Abeta are differentially localized in the blood vessel wall. Finally, as early as amyloid beta deposits can be detected, they show the presence of both human and mouse Abeta. Together, these data indicate that mouse Abeta is formed and deposited in significant amounts in the AD mouse brain and that it is deposited together with the human Abeta.
Insights
Alzheimer's disease (AD) mouse models show both human and mouse amyloid beta (Abeta) deposits in the brain. These findings reveal that mouse Abeta is significantly present and deposited alongside human Abeta in AD pathology.
Area of Science:
- Neuroscience
- Pathology
- Biochemistry
Background:
- Alzheimer's disease (AD) is characterized by amyloid beta (Abeta) peptide deposition and neurofibrillary tangles.
- Understanding Abeta production and deposition is crucial for AD research.
Purpose of the Study:
- To investigate the relationship between amyloid precursor protein (APP) production, Abeta deposition, and the origin (human vs. mouse) of Abeta in transgenic mouse models.
- To analyze the co-localization and distribution of human and mouse Abeta in the brain and vasculature of APP/PS1 mice.
Main Methods:
- Histopathological analysis using species-specific antibodies.
- Examination of neocortex and hippocampus in 6, 12, and 19-month-old APP/PS1 double and single transgenic mice.
- Assessment of Abeta deposition in brain parenchyma and leptomeningeal vessels.
Main Results:
- A significant correlation exists between human and endogenous mouse Abeta deposits; all plaques and diffuse deposits contained both.
- Human Abeta deposits were closely associated with, but did not precisely overlap with, mouse Abeta.
- Differential localization was observed, with plaque cores primarily containing human Abeta and rims containing both; blood vessels also showed co-labeling.
Conclusions:
- Mouse Abeta is formed and deposited in substantial amounts in the brains of AD transgenic mouse models.
- Both human and mouse Abeta are present from the earliest detectable stages of deposition.
- These findings highlight the complex interplay of human and endogenous Abeta in AD pathogenesis models.

